Evolus, Inc. (EOLS)

↓ Download CSV

CIK 0001570562 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Evolus, Inc. reported revenue of $297.18M, up 11.6% from the prior year. The company ran a net loss, with a net margin of -17.4% and a gross margin of 66.3%. It held $225.87M in total assets against $248.97M in total liabilities.

Key ratios (FY2025)

66.3%
Gross margin
-11.0%
Operating margin
-17.4%
Net margin
+11.6%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$297.18M$266.27M$202.09M$148.62M$99.67M$56.54M$34.92M$0
Cost of Revenue$100.07M$83.97M$64.51M$58.84M$43.53M$18.30M$8.01M$0
Gross Profit$197.11M$182.30M$137.57M$89.77M$26.91M$0
Operating Income-$32.66M-$34.41M-$49.23M-$65.33M-$44.41M-$153.07M-$98.95M-$46.14M-$11.73M
Net Income-$51.64M-$50.42M-$61.69M-$74.41M-$46.81M-$163.01M-$90.03M-$46.87M-$4.48M
EPS (Diluted)$-0.80$-0.81$-1.08$-1.33$-0.94$-4.83
Total Assets$225.87M$232.57M$189.00M$177.98M$257.48M$209.07M$240.44M$171.84M$152.23M
Total Liabilities$248.97M$227.05M$209.69M$159.48M$175.61M$282.03M$160.99M$87.46M$227.78M
Shareholders' Equity-$23.11M$5.52M-$20.69M$18.50M$81.88M-$72.96M$79.46M$84.38M-$75.54M-$7.11M
Cash & Equivalents$53.83M$86.95M$62.84M$53.92M$146.26M$102.56M$109.89M$93.16M$0
Operating Cash Flow-$42.27M-$18.00M-$34.01M-$84.91M-$33.39M-$57.87M-$93.38M-$25.67M-$13.22M
Capital Expenditures$3.44M$1.47M$473.0K$1.62M$393.0K$815.0K$345.0K$9.0K$0
Shares Outstanding65.01M63.50M57.82M56.26M55.58M33.75M33.56M27.27M16.53M